the aid library

LIST OPTIONS

Filter

8460

Recommandations et orientations concernant l’autodépistage du virus de l’hépatite C

World Health Organisation (WHO) (2021) C_WHO

Malgré les progrès récents vers la mise au point d’un traitement hautement efficace et abordable contre le virus de l’hépatite C, beaucoup de personnes infectées par ce virus ne connaissent pas leur statut. L’Organisation mondiale de la Santé (OMS) estime qu’en 2019, 58 millions ... more

Download (306)

View PDF (275)

Bénin (Indice des composantes du programme maternel et néonatal)

MNPI (2003) C2

Chaque année dans le monde, plus de 500 000 femmes et filles meurent suite aux complications imputables à la grossesse et à l’accouchement. Plus de 99% de ces décès surviennent dans des pays comme le Bénin. Et pourtant les décès maternels ne racontent qu’une partie de la vérité. En e... more

Download (751)

View PDF (1379)

WHO recommendations on the management of diarrhoea and pneumonia in HIV-infected infants and children

World Health Organization (2010) C_WHO

To improve survival and quality of life among the 2.5 million children living with HIV, a comprehensive package of prevention, care and treatment is required. This package should include management of infections such as pneumonia, diarrhoea, malaria and ear infections, as well as common opportunisti... more

Download (256)

View PDF (371)

WHO global report on trends in prevalence of tobacco use 2000-2025

World Health Organization WHO (2021) C_WHO

Progress in reducing tobacco use is a key indicator for measuring countries’ efforts to implement the WHO Framework Convention on Tobacco Control – target 3.a under the Sustainable Development Goals agenda. Countries have adopted this indicator to report progress also towards the tobacco reducti... more

External Link

The path that ends AIDS: UNAIDS Global AIDS Update 2023
recommended

UN Children's Fund UNICEF (2023) CC

This report makes clear that there is a path to end AIDS. Taking that path will help ensure preparedness to address other pandemic challenges, and advance progress across the Sustainable Development Goals. The data and real-world examples in the report make it very clear what that path is. It is not... more

Download (140)

View PDF (141)

South Africa - Country Cooperation Strategy 2023 - 2027

World Health Organization WHO (2025) C_WHO

The South African WHO Country Cooperation Strategy (CCS) 2023–2027 focuses on four key strategic priorities based on the country’s health needs and disease epidemiology, while also considering the need for building resilient health systems for UHC and health security in the post pandemic period.... more

Download (272)

View PDF (433)

South-East Asia Regional Action Plan on Programmatic Management of Latent Tuberculosis Infection

World Health Organization (WHO), Regional Office for South-East Asia (2020) C_WHO

Download (237)

View PDF (430)

Rapport mondial 2020 : Agissons maintenant - Pour combattre les profondes inégalités et mettre fin aux pandémies
recommended

ONUSIDA (2020) C_WHO

Objectifs 2020 : des avancées disparates. Le rapport de l’ONUSIDA sur l’épidémie mondiale de sida fait état d’un échec accentué par la COVID-19. Depuis 2015, 3,5 millions d’infections au VIH et 820 000 morts supplémentaires liés au sida sont imputables à des objectifs non atteints. ... more

Download (1078)

View PDF (1088)

Namibia: Nutrition guidelines for prevention and management of non-communicable diet related disease

Ministry of Health and Social Services (MOHSS) (2013) C1

Download (235)

View PDF (232)

In all our Diversity 2015 Highlights

J. Bushee; R. Gustav; J.Hows; et al. GNP+ (Global Network of people living with HIV) (2016) C2

Download (334)

View PDF (353)

Teachers for All: Inclusive Teaching for Children with Disabilities Collaborating globally to promote Inclusive Development

Ingrid Lewis and Sunit Bagree International Disability and Development Consortium’s Inclusive Education Task Group (2013) CC

External Link

Questions and Answers for Obstetrical Healthcare Providers: Pregnant Women and Zika Virus Infection

Centers for Disease Control and Prevention CDC (2022) C_CDC

English version

Download (225)

View PDF (511)

Recomendaciones para el tratamiento hospitalario de la COVID-19 en pacientes adultos ( Version 10, 2020)

G, Zambrano, E Salgato, F. M. Moyano et al. (2020) CC

Recommendations for in-patient management of COVID-19 in adult patients Version 10, November 2020.

External Link

Mycetoma: epidemiology, treatment challenges, and progress

Taha, H.; Fahal, A.; Van de Sande, W. Dovepress open access to scientific and medical research (2015) CC

Mycetoma is a specific chronic, granulomatous, inflammatory disease. It usually involves the subcutaneous tissue, most probably after traumatic inoculation of the causative organism. It has a prolonged, progressive, and indolent course, and, if untreated, it ultimately leads to destruction of the de... more

Download (236)

View PDF (254)

Adolescent Girls in Disaster & Conflict: Interventions for Improving Access to Sexual and Reproductive Health Services

S. Guthridge-Gould UNFPA (United Nations Population Fund) (2016) C2

Download (825)

View PDF (1842)

Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstratio

World Health Organization (2012)

Download (385)

View PDF (490)

Planning, Monitoring and Evaluation. Webinar 14. Companion Technical Booklet

Mont, D. UNICEF (2014)

Download (283)

View PDF (292)

EMTCT Plus - Framework for Elimination of Mother-to-Child Transmission of HIV, Syphilis, Hepatitis B, and Chagas

F. Pérez; M. B. Mello; L. Sereno; et al. Pan American Health Organization; World Health Organization (2017) C_WHO

The objective of the EMTCT Plus initiative is to achieve and sustain the elimination of mother-to-child transmission of HIV, syphilis, Chagas, and perinatal hepatitis B (HBV) as a public health threat. It embraces the principles and lines of action of the Strategy for Universal Access to Health a... more

Download (424)

View PDF (646)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (325)

View PDF (321)

Manual for male circumcision under local anaesthesia and HIV prevention services for adolescent boys and men
recommended

World Health Organization WHO (2018) C_WHO

The path that ends AIDS: UNAIDS Global AIDS Update 2023 recommended

Rapport mondial 2020 : Agissons maintenant - Pour combattre les profondes inégalités et mettre fin aux pandémies recommended

Manual for male circumcision under local anaesthesia and HIV prevention services for adolescent boys and men recommended

The path that ends AIDS: UNAIDS Global AIDS Update 2023
recommended

Rapport mondial 2020 : Agissons maintenant - Pour combattre les profondes inégalités et mettre fin aux pandémies
recommended

Manual for male circumcision under local anaesthesia and HIV prevention services for adolescent boys and men
recommended